Clinical trials: peripheral blood stem cell transplantation, open to volunteers
Myeloid Chimerism
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
Background: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second transplant to people whose disease has returned but still have some…
- Trial name
- NCT04008368
- Testing
- CliniMACS CD34 Reagent
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myeloid Leukemia, Graft Versus Host Disease
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute…
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Trial name
- NCT06996119
- Testing
- Biospecimen Collection, Busulfan, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Hematological Malignancy
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate .
- Trial name
- NCT03850366
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously…
- Trial name
- NCT05039073
- Testing
- Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Acute Leukemia, Acute Lymphoblastic Lymphoma
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow…
- Trial name
- NCT06803745
- Testing
- 200 cGy or 400 cGy total body irradiation (TBI)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Severe Aplastic Anemia, Hypo-Plastic MDS
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Background: Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant.
- Conditions
- Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT03173937
- Testing
- Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
- Trial name
- NCT06704542
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Allogeneic HSCT, Posttransplant Complications
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression.
- Conditions
- Allogeneic HSCT, Posttransplant Complications, GvHD, Relapse
- Trial name
- QiNKT-HSCT (NCT07570407)
- Testing
- blood draw
- Where
- Czechia
- Volunteers
- 75 people
- Sponsor
- University Hospital Pilsen
B-cell Lymphoma, Burkitt Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT).
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04491370
- Testing
- Polatuzumab vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies.
- Conditions
- T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
- Trial name
- nanobody CD5 (NCT07070323)
- Testing
- Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- Beijing GoBroad Hospital
Primary Graft Failure
REVEAL Biomarkers of Engraftment After Alternative Donor HSCT
The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed.
- Trial name
- REVEAL (NCT03541889)
- Testing
- FLT imaging and TK1 blood measurements
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07365306
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Primary Progressive Multiple Sclerosis, Multiple Sclerosis
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
- Conditions
- Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06900192
- Testing
- Orca-Q, myeloablative regimen
- Volunteers
- 10 people
- Sponsor
- Stanford University
Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
This is a single-center prospective, non-randomized controlled clinical study in China using CliniMACS TCRα/β+ cell depleted stem cell haploidentical donors versus conventional Beijing protocol for haploidentical hematopoietic…
- Conditions
- Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation, Child, Only, Haploidentical Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06423131
- Testing
- TCRαβ Depleted haploidentical HCT
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sijia Gu
Crohn Disease
Stem Cell Transplantation in Crohn's Disease
Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit.
- Trial name
- NCT04224558
- Testing
- Mesna, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
Richter Syndrome
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
This single-arm, multicenter, open-label phase II trial evaluates the efficacy and safety of rituximab + pirtobrutinib + lisaftoclax + liposomal mitoxantrone in adults with CLL-transformed Richter syndrome (CLL-RS).
- Trial name
- RPLM-RS (NCT07831395)
- Testing
- Lisaftoclax (APG-2575), Rituximab, Pirtobrutinib
- Where
- 6 sites in China
- Volunteers
- 23 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Failure, Sickle Cell Disease
Allo HSCT for High Risk Hemoglobinopathies
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation…
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Trial name
- NCT06872333
- Testing
- Alemtuzumab, Total Body Irradiation, Cell Infusion
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not…
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma
- Trial name
- NCT04684368
- Testing
- Biospecimen Collection, Carboplatin, Etoposide
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 160 people
- Sponsor
- Children's Oncology Group
Bone Marrow Transplant, Stem Cell Transplant
Shingrix In Recipients of Allogeneic Transplants
This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant…
- Trial name
- Allo (NCT05775718)
- Testing
- Zoster Vaccine Recombinant
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Colorado, Denver